Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/25/2026

1. AKAM
2. COST
3. SPY
4. ZS
5. META
6. NVDA
7. ULS
8. DRI
9. CRL
10. VEON

Go back to Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Merck & Co. (NYSE: MRK) Delayed: 147.78 -0.2 (0.14%)
Previous Close $147.98    52 Week High $65.46 
Open $148.06    52 Week Low $47.97 
Day High $149.98    P/E 100.53 
Day Low $147.48    EPS $1.47 
Volume 2,685,337